Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 48,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Bladder Cancer
Interventions: Neoadjuvant Therapy, Upfront radical cystectomy; Drug · Procedure
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions: encorafenib, Binimetinib, Cetuximab; Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: New York, New York • Germantown, Tennessee

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more

Conditions: Patellofemoral Pain Syndrome
Interventions: Intra-Articular Hyaluronic Acid-Euflexxa; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Advanced Metastatic
Interventions: TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine; Biological
Lead sponsor: Mary Crowley Medical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ductal Carcinoma in Situ of the Breast
Interventions: Observation; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Substance-Related Disorders
Interventions: Experimental memory training, Comparator memory training 1, Comparator memory training 2; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Peer-oriented intervention, Group cognitive behavioral therapy (CBT); Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 74 Years
Enrollment: 746 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: Ovarian Cancer
Interventions: catumaxomab; Drug
Lead sponsor: Neovii Biotech; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Tucson, Arizona • Stanford, California • Orlando, Florida + 9 more

Conditions: Pain
Interventions: Ropivacaine 0.1%, Ropivacaine 0.2%, Normal saline, On-Q ® elastomeric pump; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sarcoma,Soft Tissue
Interventions: INT230-6, Eribulin, Trabectedin, Pazopanib; Drug
Lead sponsor: Intensity Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 5 more

Conditions: Subcutaneous Fat
Interventions: CBL-514 Injection, 0.9% Sodium Chloride; Drug
Lead sponsor: Caliway Biopharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Encinitas, California • Aventura, Florida • Alpharetta, Georgia + 8 more

Conditions: Thymidine Kinase 2 Deficiency
Interventions: Observational retrospective data; Other
Lead sponsor: Zogenix MDS, Inc.; Industry
Eligibility: Not listed
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Indianapolis, Indiana • Akron, Ohio + 1 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Yoga Nidra; Behavioral
Lead sponsor: Samueli Institute for Information Biology; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Epilepsy, Partial
Interventions: Levetiracetam, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 4 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more

Conditions: Lymphoma
Interventions: CUDC-427; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions: Lidoderm; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 11
States / cities: Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more

Conditions: Breast Cancer
Interventions: Acupuncture, Sham Acupuncture, Wait-List Control (WLC), Questionnaires; Procedure · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Autism Spectrum Disorder, ASD, Autism, PDD
Interventions: Cord Blood Infusion, Placebo; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 2 Years to 7 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Age-Related Macular Degeneration
Interventions: Ranibizumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pancreatic Cancer
Interventions: Walking Program; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Constipation
Interventions: Senna+ docusate, placebo; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Induction of Labor Affected Fetus / Newborn
Interventions: Outpatient Foley catheter; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 2,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Newark, Delaware • Plainsboro, New Jersey • Philadelphia, Pennsylvania + 3 more

Search by objective public record fields.

Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Effectiveness Trial for Evaluating IAHA for PFPS

Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast

Effects of Repeated Memory Training on Memory Function and Addiction Related Processes

A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Use of On-Q Pump for Pain Post C-Section

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency

Yoga as a Therapy for Traumatic Experiences

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

The Effect of Acupuncture on Cancer-Related Cognitive Difficulties

Cord Blood Infusion for Children With Autism Spectrum Disorder

Study EvAluating Genotypes While Using Lucentis 2

Fatigue and Pancreas and Bile Duct Cancer Study

The Use of SennaS for Prevention of Post-operative Constipation After Urogynecologic Surgery

Cervical Ripening as an Outpatient Method Using the Foley (COMFORT)